Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study

Abstract Background Locoregional tumor control and prolonged survival for dogs with genitourinary carcinoma (CGUC) reportedly are achievable using treatment with radiotherapy (RT) with or without adjunctive chemotherapy and nonsteroidal anti‐inflammatory drugs (NSAIDs). Objectives To characterize ev...

Full description

Bibliographic Details
Main Authors: Benoit Clerc‐Renaud, Tracy L. Gieger, Susan M. LaRue, Michael W. Nolan
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Journal of Veterinary Internal Medicine
Subjects:
Online Access:https://doi.org/10.1111/jvim.16078
id doaj-af5be1148f234f188d592293a84fa2d3
record_format Article
spelling doaj-af5be1148f234f188d592293a84fa2d32021-03-26T10:53:09ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-03-013521052106110.1111/jvim.16078Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective studyBenoit Clerc‐Renaud0Tracy L. Gieger1Susan M. LaRue2Michael W. Nolan3Flint Animal Cancer Center Colorado State University Fort Collins Colorado USADepartment of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USAFlint Animal Cancer Center Colorado State University Fort Collins Colorado USADepartment of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USAAbstract Background Locoregional tumor control and prolonged survival for dogs with genitourinary carcinoma (CGUC) reportedly are achievable using treatment with radiotherapy (RT) with or without adjunctive chemotherapy and nonsteroidal anti‐inflammatory drugs (NSAIDs). Objectives To characterize event‐free and overall survival after treatment of CGUC using NSAIDs, mitoxantrone (MTX), and a standardized RT protocol (57 Gy in 20 fractions). Animals Fifty‐one client‐owned dogs treated between 2008 and 2017. Methods Dogs were retrospectively categorized into treatment groups: (a) first‐line concurrent chemoradiotherapy (≥1 dose of MTX started within 1 month of RT); (b) first‐line chemotherapy (MTX administered for >1 month before RT without tumor progression); (c) RT as a salvage procedure (MTX, surgery or both with subsequent locoregional tumor progression before RT). Treatment‐induced toxicoses, event‐free survival (EFS), and overall survival times (OSTs) were recorded. The influence of demographics, staging, and treatment‐related factors on survival was assessed using Cox proportional hazards modeling. Results Median EFS and OST for all dogs were 260 and 510 days with no significant differences among groups 1 (n = 39), 2 (n = 4), and 3 (n = 8). Both EFS and OST were shorter in dogs with moderate to severe clinical signs (P < .001 and P < .001, respectively); OST was shorter in dogs with prostatic involvement (P = .02). Permanent urinary incontinence developed in 16 dogs (31%) at a median of 70 days postirradiation; other toxicoses were mild and self‐limiting. Conclusions and Clinical Importance Mild clinical signs and lack of prostate involvement were associated with favorable prognosis for survival. Client education regarding the risk of urinary incontinence is warranted.https://doi.org/10.1111/jvim.16078definitive‐intentdogsintensity‐modulatedradiotherapyurogenital carcinoma
collection DOAJ
language English
format Article
sources DOAJ
author Benoit Clerc‐Renaud
Tracy L. Gieger
Susan M. LaRue
Michael W. Nolan
spellingShingle Benoit Clerc‐Renaud
Tracy L. Gieger
Susan M. LaRue
Michael W. Nolan
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study
Journal of Veterinary Internal Medicine
definitive‐intent
dogs
intensity‐modulated
radiotherapy
urogenital carcinoma
author_facet Benoit Clerc‐Renaud
Tracy L. Gieger
Susan M. LaRue
Michael W. Nolan
author_sort Benoit Clerc‐Renaud
title Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study
title_short Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study
title_full Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study
title_fullStr Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study
title_full_unstemmed Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study
title_sort treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: a retrospective study
publisher Wiley
series Journal of Veterinary Internal Medicine
issn 0891-6640
1939-1676
publishDate 2021-03-01
description Abstract Background Locoregional tumor control and prolonged survival for dogs with genitourinary carcinoma (CGUC) reportedly are achievable using treatment with radiotherapy (RT) with or without adjunctive chemotherapy and nonsteroidal anti‐inflammatory drugs (NSAIDs). Objectives To characterize event‐free and overall survival after treatment of CGUC using NSAIDs, mitoxantrone (MTX), and a standardized RT protocol (57 Gy in 20 fractions). Animals Fifty‐one client‐owned dogs treated between 2008 and 2017. Methods Dogs were retrospectively categorized into treatment groups: (a) first‐line concurrent chemoradiotherapy (≥1 dose of MTX started within 1 month of RT); (b) first‐line chemotherapy (MTX administered for >1 month before RT without tumor progression); (c) RT as a salvage procedure (MTX, surgery or both with subsequent locoregional tumor progression before RT). Treatment‐induced toxicoses, event‐free survival (EFS), and overall survival times (OSTs) were recorded. The influence of demographics, staging, and treatment‐related factors on survival was assessed using Cox proportional hazards modeling. Results Median EFS and OST for all dogs were 260 and 510 days with no significant differences among groups 1 (n = 39), 2 (n = 4), and 3 (n = 8). Both EFS and OST were shorter in dogs with moderate to severe clinical signs (P < .001 and P < .001, respectively); OST was shorter in dogs with prostatic involvement (P = .02). Permanent urinary incontinence developed in 16 dogs (31%) at a median of 70 days postirradiation; other toxicoses were mild and self‐limiting. Conclusions and Clinical Importance Mild clinical signs and lack of prostate involvement were associated with favorable prognosis for survival. Client education regarding the risk of urinary incontinence is warranted.
topic definitive‐intent
dogs
intensity‐modulated
radiotherapy
urogenital carcinoma
url https://doi.org/10.1111/jvim.16078
work_keys_str_mv AT benoitclercrenaud treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy
AT tracylgieger treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy
AT susanmlarue treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy
AT michaelwnolan treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy
_version_ 1724202170885079040